Get started
Author

Yosuke Kawashima

Observed names: Y. Kawashima, YOSUKE KAWASHIMA
ORCID: 0000-0002-9824-6572
Observed ORCID: 0000-0002-9824-6572
OpenAlex ID: A5048623459
Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
2018 · Yukihiro Toi, Shunichi Sugawara, et al. · JAMA Oncology · 356
PDF
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab
2018 · Yukihiro Toi, Shunichi Sugawara, et al. · The Oncologist · 297
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
2021 · Yosuke Kawashima, Tatsuro Fukuhara, et al. · The Lancet Respiratory Medicine · 140
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations
2023 · Yusuke Okuma, Kaoru Kubota, et al. · JAMA Oncology · 97
Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer
2019 · Mari Aso, Yukihiro Toi, et al. · The Oncologist · 57
PDF
Five Cases of Cytokine Release Syndrome in Patients Receiving Cytotoxic Chemotherapy Together With Nivolumab Plus Ipilimumab: A Case Report
2023 · Yoshimasa Shiraishi, Takaaki Tokito, et al. · Journal of Thoracic Oncology · 28
PDF
A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non–Small Cell Lung Cancer: TORG1630
2022 · Yuri Taniguchi, Tsuneo Shimokawa, et al. · Clinical Cancer Research · 26
PDF
Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab
2019 · Jun Sugisaka, Yukihiro Toi, et al. · JMA Journal · 24
Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib
2017 · Ryo Ariyasu, Atsushi Horiike, et al. · Anti-Cancer Drugs · 23
Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer
2021 · Kana Ono, Hirotaka Ono, et al. · Cancer Medicine · 19
Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02)
2023 · Tsukasa Hasegawa, Ryo Ariyasu, et al. · Cancer Chemotherapy and Pharmacology · 13
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis ( TOPGAN2020 ‐02)
2022 · Hisashi Tanaka, Hiroaki Sakamoto, et al. · Thoracic Cancer · 12
PDF
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
2023 · Daisuke Hazama, Kenji Nakahama, et al. · JTO Clinical and Research Reports · 10
PDF
Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers
2021 · Tomoiki Aiba, Chieko Hattori, et al. · PLoS ONE · 10
PDF
Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs
2018 · SATOSHI WATANABE, OU YAMAGUCHI, et al. · Anticancer Research · 10
PDF
Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study ( HOT2101 )
2024 · Kosuke Tsuji, Hidenori Mizugaki, et al. · Cancer Science · 9
PDF
Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.
2019 · Yukihiro Toi, Yuichiro Kimura, et al. · Sarcoidosis vasculitis and diffuse lung diseases · 9
PDF
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
2023 · Yasunori Murata, Shigeru Tanzawa, et al. · JTO Clinical and Research Reports · 8
PDF
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first‐line treatment including immune checkpoint inhibitors: A retrospective multicenter study ( TOPGAN 2021‐01)
2022 · Shinya Uematsu, Satoru Kitazono, et al. · Thoracic Cancer · 8
PDF
Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-Doublet Chemotherapy for Non–Small Cell Lung Cancer Harboring EGFR Mutation
2025 · Shintaro Kanda, Seiji Niho, et al. · Clinical Cancer Research · 7
A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung
2020 · Kyoji Tsurumi, Yosuke Kawashima, et al. · JMA Journal · 7
Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803.
2013 · Yosuke Kawashima, Akira Inoue, et al. · Journal of Clinical Oncology · 6
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01
2024 · Hisashi Tanaka, Tomonori Makiguchi, et al. · European Journal of Cancer · 5
PDF
Association between Immune-Related Adverse Events and Atezolizumab in Previously Treated Patients with Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
2024 · Hidetoshi Hayashi, Makoto Nishio, et al. · Cancer Research Communications · 5
PDF
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study
2025 · Shigeru Tanzawa, Hiroshige Yoshioka, et al. · Therapeutic Advances in Medical Oncology · 4
Works count: 99
Citation count: 1,230
H-index: 12
I10-index: 15
Year
Topic
Type